Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Operating Leases: 2022-2025

Historic Operating Leases for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $85,000.

  • NewAmsterdam Pharma Co N.V's Operating Leases fell 68.05% to $85,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $85,000, marking a year-over-year decrease of 68.05%. This contributed to the annual value of $202,000 for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma Co N.V's Operating Leases is $85,000, which was down 17.48% from $103,000 recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Operating Leases registered a high of $328,000 during Q2 2024, and its lowest value of $64 during Q2 2023.
  • For the 3-year period, NewAmsterdam Pharma Co N.V's Operating Leases averaged around $160,152, with its median value being $137,000 (2025).
  • Per our database at Business Quant, NewAmsterdam Pharma Co N.V's Operating Leases soared by 512,400.00% in 2024 and then tumbled by 68.60% in 2025.
  • Over the past 4 years, NewAmsterdam Pharma Co N.V's Operating Leases (Quarterly) stood at $60,000 in 2022, then reached $64 in 2023, then spiked by 512,400.00% to $202,000 in 2024, then crashed by 68.05% to $85,000 in 2025.
  • Its last three reported values are $85,000 in Q3 2025, $103,000 for Q2 2025, and $137,000 during Q1 2025.